This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cane, P. A.
Right arrow Articles by Pillay, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cane, P. A.
Right arrow Articles by Pillay, D.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, July 2001, p. 2652-2654, Vol. 39, No. 7
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.7.2652-2654.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Resistance-Associated Mutations in the Human Immunodeficiency Virus Type 1 Subtype C Protease Gene from Treated and Untreated Patients in the United Kingdom

Patricia A. Cane,1,* Annemiek de Ruiter,2 Philip Rice,3 Martin Wiselka,4 Ray Fox,5 and Deenan Pillay1

PHLS Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham,1 Department of Genito-Urinary Medicine, Guys and St. Thomas' NHS Trust,2 and Department of Virology, St. Georges Hospital,3 London, Department of Infectious Diseases, Leicester Royal Infirmary, Leicester,4 and Department of Infectious Diseases, Gartnavel Hospital, Glasgow,5 United Kingdom

Received 8 December 2000/Returned for modification 21 January 2001/Accepted 20 April 2001

This work reports the variability of human immunodeficiency virus type 1 (HIV-1) protease from treated and untreated patients infected with HIV-1 subtype C in the United Kingdom. The most common primary mutation observed in treated patients was L90M. D30N, M46I, V82A/F, and I84V were seen rarely. M36I and I93L mutations were observed in nearly all samples from both treated and untreated patients and so cannot be considered as resistance-associated mutations in this subtype.

* Corresponding author. Mailing address: PHLS Antiviral Susceptibility Reference Unit, Division of Immunity and Infection, University of Birmingham Medical School, Birmingham B15 2TT, United Kingdom. Phone: 0121 414 6972. Fax: 0121 414 3454. E-mail: p.cane{at}bham.ac.uk.

Journal of Clinical Microbiology, July 2001, p. 2652-2654, Vol. 39, No. 7
0095-1137/01/$04.00+0   DOI: 10.1128/JCM.39.7.2652-2654.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Waleria-Aleixo, A., Martins, A. N., Arruda, M. B., Brindeiro, R. M., Da-Silva, R. M., Nobre, F. F., Greco, D. B., Tanuri, A. (2008). Drug Resistance Mutation Profile and Accumulation Kinetics in Human Immunodeficiency Virus-Positive Individuals Infected with Subtypes B and F Failing Highly Active Antiretroviral Therapy Are Influenced by Different Viral Codon Usage Patterns. Antimicrob. Agents Chemother. 52: 4497-4502 [Abstract] [Full Text]  
  • Mosebi, S., Morris, L., Dirr, H. W., Sayed, Y. (2008). Active-Site Mutations in the South African Human Immunodeficiency Virus Type 1 Subtype C Protease Have a Significant Impact on Clinical Inhibitor Binding: Kinetic and Thermodynamic Study. J. Virol. 82: 11476-11479 [Abstract] [Full Text]  
  • Gonzalez, L. M. F., Aguiar, R. S., Afonso, A., Brindeiro, P. A., Arruda, M. B., Soares, M. A., Brindeiro, R. M., Tanuri, A. (2006). Biological characterization of human immunodeficiency virus type 1 subtype C protease carrying indinavir drug-resistance mutations.. J. Gen. Virol. 87: 1303-1309 [Abstract] [Full Text]  
  • Gonzalez, L. M. F., Brindeiro, R. M., Aguiar, R. S., Pereira, H. S., Abreu, C. M., Soares, M. A., Tanuri, A. (2004). Impact of Nelfinavir Resistance Mutations on In Vitro Phenotype, Fitness, and Replication Capacity of Human Immunodeficiency Virus Type 1 with Subtype B and C Proteases. Antimicrob. Agents Chemother. 48: 3552-3555 [Abstract] [Full Text]  
  • Rhee, S.-Y., Liu, T., Ravela, J., Gonzales, M. J., Shafer, R. W. (2004). Distribution of Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Mutation Patterns in 4,183 Persons Undergoing Genotypic Resistance Testing. Antimicrob. Agents Chemother. 48: 3122-3126 [Abstract] [Full Text]  
  • Grossman, Z., Paxinos, E. E., Averbuch, D., Maayan, S., Parkin, N. T., Engelhard, D., Lorber, M., Istomin, V., Shaked, Y., Mendelson, E., Ram, D., Petropoulos, C. J., Schapiro, J. M. (2004). Mutation D30N Is Not Preferentially Selected by Human Immunodeficiency Virus Type 1 Subtype C in the Development of Resistance to Nelfinavir. Antimicrob. Agents Chemother. 48: 2159-2165 [Abstract] [Full Text]  
  • Masquelier, B., Droz, C., Dary, M., Perronne, C., Ferre, V., Spire, B., Descamps, D., Raffi, F., Brun-Vezinet, F., Chene, G., the APROCO/COPILOTE Study Group, (2003). R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing Regimen. Antimicrob. Agents Chemother. 47: 3623-3626 [Abstract] [Full Text]  
  • Brindeiro, P. A., Brindeiro, R. M., Mortensen, C., Hertogs, K., De Vroey, V., Rubini, N. P. M., Sion, F. S., De Sa, C. A. M., Machado, D. M., Succi, R. C. M., Tanuri, A. (2002). Testing Genotypic and Phenotypic Resistance in Human Immunodeficiency Virus Type 1 Isolates of Clade B and Other Clades from Children Failing Antiretroviral Therapy. J. Clin. Microbiol. 40: 4512-4519 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»